IPSC · Century Therapeutics, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on IPSC. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About IPSC · Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Live Quote
BUY (score +7) · 12-1 mom 281.5% · RSI 57.9 · above_both · -18.0% from high
Targets blend Wall Street consensus (4 analysts: low $2.00 / mean $4.75 / high $8.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
The investigation was triggered by high Form 4 filing volume (3 in last 14 days), but after reading each transaction code, all recent filings are automatic tax-withholding sales from RSU vesting schedules — zero open-market discretionary purchases in the past 90 days. The CEO did receive a large options grant (945K shares at $1.84) in February, which is meaningful alignment of interests, but it is compensation, not a discretionary buy signal. Century has genuine catalysts: CNTY-813 for Type 1 Diabetes IND expected Q4 2026 with initial clinical data in H2 2027; oral presentation at ADA on June 8 showed durable glucose control >8 months and immune evasion without immunosuppression. A $135M private placement in January extended runway to Q1 2029, eliminating near-term dilution risk. However, IPSC is a pre-revenue biotech burning ~$23-24M/quarter with no product revenue and EV/EBITDA deeply negative — there is no conventional valuation framework that supports the current price on fundamentals alone.